HIV
Also known as: AIDS · antiretroviral therapy · ART · PEP · PrEP
Free to read — no account needed. Sign in only to bookmark this disease and track your study progress.
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV
U.S. Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents · 2025 · Living guideline, updated September 2025
A continuously updated US federal guideline on antiretroviral therapy for adults and adolescents with HIV, spanning when to start treatment, regimen selection, laboratory monitoring, management of treatment-experienced patients, special populations and drug interactions.
- The guideline is maintained as a living document by an HHS panel convened under the NIH Office of AIDS Research, with the most recent revision dated September 2025. source
- Recent revisions added guidance on starting therapy in early infection and during hospitalisation, and a chapter on cardiovascular and metabolic complications. source
EACS Guidelines
European AIDS Clinical Society (EACS) · 2025 · 13.0
The European reference guideline for the care of people living with HIV, covering prevention, antiretroviral treatment, co-infections, and comorbidity management. Version 13.0 is a major revision, reorganised into a part on HIV and related infections and a part on comorbidities.
US vs EU key differences
- Document architecture differs: the US HHS publishes separate living guidelines for adult/adolescent antiretroviral therapy, adult and pediatric opportunistic infections, and perinatal HIV, whereas EACS issues one consolidated European document. source
- EACS restructured its 2025 version 13.0 into two parts: Part I on antiretrovirals, drug-drug interactions and co-infections (opportunistic infections, STIs, viral hepatitis, immunisation), and Part II on non-infectious comorbidities plus topics such as travel and solid organ transplantation. source
- Both sides are currently maintained: EACS released a major revision (version 13.0) in 2025, and the US HHS panel updates its adult/adolescent ARV guideline on a rolling basis, with a substantive update in September 2025. source
What changed recently
- EU12.1 → 13.02025-10-01
Version 13.0 restructured the guidelines into two parts, added a new consolidated Substance Use section covering alcohol, opioid use and chemsex, and extensively rewrote the obesity guidance to cover pharmacotherapy and bariatric surgery. Recommended first-line ART regimens for treatment-naive adults were left unchanged from v12.1, and the lipodystrophy section was retired.
- USSeptember 12, 2024 update → Living guideline, updated September 20252025-09-25
The September 2025 revision added a dedicated chapter on cardiovascular and metabolic complications as people with HIV approach normal life expectancy, and retired the standalone statin primary-prevention section in favour of the ACC/AHA multisociety dyslipidaemia guidance. It also revised laboratory monitoring intervals, added subsections on starting ART in early infection and in hospitalised patients, and expanded cost guidance around long-acting injectables.
source ↗curation confidence 90%
See the full update feed for changes across every system.